Novo Nordisk's Q3 revenue growth was mainly fueled by strong sales of the Wegovy pill, while other group revenues declined about 2%. The company faces significant pricing pressure with net price declines of 10–15% for Ozempic and 30–35% for Wegovy, alongside risks from upcoming patent expiries. Long-term prospects depend on diversifying its drug portfolio beyond semaglutide, focusing on new franchises like CagriSema and Zenagamtide to reduce concentration and pricing risks. The outlook remains cautiously optimistic as patient numbers grow and the Wegovy pill gains traction.
Novo Nordisk shares are trading at USD 41.44 on Pluang as of Nov 12, 2026 17:51 WIB, showing a modest 0.85% gain for the day. Despite strong sales growth in some areas, 99% of Pluang order activity is currently selling the stock. The company’s market cap stands at $179.66 billion, reflecting its significant presence in the health sector.
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
The FDA requires all makers of GLP-1 medications to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and possibly permanent vision loss. This decision follows a review of c...
Novo Resources Corp. has released an updated corporate presentation outlining its strategic priorities, exploration results, and project advancements. The presentation highlights significant progress in Novo's gold exploration portfolio, including pr...
Novo Nordisk's Q3 results exceeded expectations, driven by a 53% increase in pill sales and strong net patient growth, dispelling fears of oral product cannibalization. The company is also reducing capital expenditures and expanding free cash flow, s...
